Medpace Holdings, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 45/100
What the filing says
Medpace reported Q2 2026 revenue of $707.3M (+17.2% YoY) with net new business awards of $795.7M (+28.2% YoY) and a 1.13x book-to-bill ratio. GAAP net income was $121.4M ($4.25/diluted share) vs. $90.3M ($3.10/share) prior year; net margin expanded to 17.2% from 15.0%. The company raised full-year 2026 guidance to $2.805–$2.885B revenue (10.9–14.0% growth) with GAAP net income $494–$514M and diluted EPS $17.25–$17.95. Backlog increased 4.9% to $3.014B; the company repurchased 705,616 shares for $294.7M in Q2.
Why this rating
Strong topline/margin growth and raised guidance are positive; however, absolute dollar scale (~$1.4B YTD revenue on $7B market cap, ~2% of cap) is routine quarterly performance relative to company size.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.